Novacyt: on these numbers, the cheapest stock on the market
AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the future?
Novacyt (EURONEXT GROWTH: ALNOV; LON: NCYT ), the clinical diagnostics specialist and superstar performer from 2020, updated on trading for the year ending 31 December 2020. Here are the astonishing highlights from an incredible year:
EBITDA profitability above €210m (£187m), representing an EBITDA margin of more than 67%, after adding 124 people to the payroll.
Cash at 31 December 2020 was…
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Fundamental Asset Management
Buy any of our portfolios with our associates.
Previous article Next article
For access to the top news and insights from the investment worldREGISTER FREE
More on Novacyt SA
After a volatile start to 2021, the share price of last year’s top AIM performer received…
AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the…